Business Wire

CA-SYSDIG,-INC.

13.1.2021 13:02:34 CET | Business Wire | Press release

Share
Sysdig Usage Report Finds Shifting Container Security Left is Not Enough

Sysdig, Inc., the secure DevOps leader, today announced findings from its Sysdig 2021 Container Security and Usage Report. While usage reveals organizations are shifting left by scanning images during the build phase, DevOps teams are still leaving their environments open to attack. The report also looks at trends, finding a 310 percent growth in container density since 2017.

The fourth annual report reveals how global Sysdig customers of all sizes and across industries are using and securing container environments. This real-world, real-time data provides insight into usage of the nearly one billion containers Sysdig customers run yearly, including security risks, container utilization, and services used. Read the Sysdig 2021 Container Security and Usage blog .

Among its findings, the report states that while 74 percent of customers are scanning before deployment, still more than half (58 percent) of containers are running as root. There are some containers that should run as root—security and system daemons for example—but this is a small portion of total containers. These risky configurations leave easy access to potentially compromise the system and access sensitive data. This finding stresses the need for security throughout the lifecycle of a container image—fixing vulnerabilities is not enough.

Highlights From the Report

Container density grows 170% since 2018

Over the past three years, the median number of containers-per-host more than doubled from 15 in 2018 to 41 today, indicating a growth in efficiency and a shift in cost savings as containers mature. This reveals a continued focus on optimization.

Prometheus continues to grow, 35% YoY

Open source adoption is broader than just Kubernetes as organizations are shifting toward Prometheus as the standard approach to monitoring container environments. The use of Prometheus metrics among Sysdig customers grew 35 percent year-over-year.

Docker down, containerd and CRI-O up 4X

In 2017, Docker represented 99 percent of containers in use at that time. Today, that number has fallen to 50 percent, down from 79 percent in October 2019. While Docker revolutionized containers, organizations are rapidly switching to newer runtimes like containerd and CRI-O.

21% of containers live less than 10 seconds

The ephemeral nature of containers is a unique efficiency advantage, yet it can be a challenge in managing issues around security, health, and performance. The short life of containers reaffirms the need for container-specific tools for security and monitoring. For example, organizations need metric collection with intervals of less than 10 seconds and a detailed record of what occurred when the container was alive.

“With the high-profile breaches we are seeing and the accelerated adoption of containers in production, the container security risk is now on the radar of CISOs. Across millions of containers that we have studied, it’s clear that organizations are shifting security left, but they are neglecting critical best practices,” said Suresh Vasudevan, chief executive officer of Sysdig. “Container security has to span the entire software development lifecycle. Until organizations fix risky configurations, protect their runtime environments, and invest in container forensics, we will see an increase in container security breaches. I expect we will see several high-impact breaches before we release our next report.”

Other Interesting Findings

  • Falco, the open source runtime project for cloud-native environments created by Sysdig and donated to the CNCF, has seen a 300 percent increase in Docker Hub downloads over the last year.
  • The use of golang increased to 66 percent, a 470 percent jump since last year.
  • 63 percent of container images are replaced within two weeks or less, signifying a more frequent code deployment rate.

Learn More About this Report

About Sysdig

Sysdig is driving the secure DevOps movement, empowering organizations to confidently secure containers, Kubernetes, and cloud services. With the Sysdig Secure DevOps Platform, cloud teams secure the build pipeline, detect and respond to runtime threats, continuously validate compliance, and monitor and troubleshoot cloud infrastructure and services. Sysdig is a SaaS platform, built on an open source stack that includes Falco and sysdig OSS, the open standards for runtime threat detection and response. Hundreds of companies rely on Sysdig for container and Kubernetes security and visibility. Learn more at www.sysdig.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye